文献速递妇科

贝伐珠单抗联合剂量密集紫杉醇一线治疗晚期卵巢癌的II期试验

Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-08-01

单中心II期研究纳入33例III/IV期上皮性卵巢癌患者,术后接受卡铂(AUC 5)、周疗紫杉醇(80mg/m2)和贝伐珠单抗(15mg/kg)每3周方案至少6周期。23例(77%)完成至少4周期,中位无进展生存期在R0组为22.4个月,应答者Flt-3L平均升高显著高于无应答者。

要点

  • 23例(77%)完成至少4周期治疗,21例(70%)完成至少6周期。
  • R0组中位无进展生存期22.4个月,优于残留≤1cm组的16.9个月(HR 1.71,95%CI 0.58-4.98,p=0.33)。
  • 应答者Flt-3L平均升高83.4 pg/mL,显著高于无应答者的28 pg/mL(p=0.05)。

核心结论

  • 辅助贝伐珠单抗联合剂量密集化疗毒性可接受,完成4周期治疗的可能性高。
  • Flt-3L动态变化可能作为治疗应答的预测标志物。

研究设计与样本

  • 单中心II期研究,经IRB批准后入组33例III期或IV期上皮性卵巢癌患者,均在初次肿瘤细胞减灭术后接受治疗。
  • 方案为卡铂(AUC 5)、周疗紫杉醇(80mg/m2)和贝伐珠单抗(15mg/kg)每3周一次,至少6周期。
  • 主要终点为至少4周期治疗的可耐受性,目标治疗成功率>60%;次要终点包括无进展生存期和应答率。

主要发现

  • 30例可评估患者中23例(77%)按方案完成至少4周期治疗,治疗成功率>60%的后验概率为0.77。
  • 21例(70%)完成至少6周期治疗。
  • R0组中位无进展生存期22.4个月,残留≤1cm组16.9个月(HR 1.71,95%CI 0.58-4.98,p=0.33),残留>1cm组16.9个月(HR 3.75,95%CI 1.05-13.34,p=0.04)。
  • 应答者Flt-3L平均升高83.4 pg/mL,无应答者为28 pg/mL(p=0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles. The primary endpoint was tolerability of at least 4cycles of therapy, with a target treatment success rate of >60%. Secondary endpoints included progression-free survival (PFS) and response rate. Plasma biomarkers were analyzed by the multiplex ELISA assays. RESULTS: Thirty-three patients were enrolled with 30 evaluable patients receiving at least one cycle of combination treatment. Twenty-three patients (77%) were able to complete at least 4cycles of therapy per protocol, and the posterior probability that the treatment success rate is >60% is 0.77. Twenty-one patients (70%) were able to complete ≥6cycles of therapy. Median PFS was 22.4months for patients with optimal (R0) compared to 16.9months for optimal≤1cm (HR 1.71, 95% CI 0.58-4.98, p=0.33), and 16.9months for suboptimal>1cm (HR 3.75, 95% CI 1.05-13.34, p=0.04) disease. Increases in mean Flt-3L was significantly higher in responders versus non-responders (83.4 vs. 28pg/mL, p=0.05). CONCLUSIONS: Adjuvant bevacizumab with dose-dense chemotherapy is associated with acceptable toxicity and a high likelihood of completing 4cycles of therapy. Dynamic changes in Flt-3L may represent a predictive marker to treatment response.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fleming ND, Coleman RL, Tung C, et al. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 28774461. doi:10.1016/j.ygyno.2017.07.137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。